UroGen Pharma
Logotype for UroGen Pharma Ltd

UroGen Pharma (URGN) investor relations material

UroGen Pharma 3rd Annual Guggenheim Healthcare Innovation Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for UroGen Pharma Ltd
3rd Annual Guggenheim Healthcare Innovation Conference summary10 Nov, 2026

Commercial launch

  • ZUSDURI’s permanent J-code took effect in January; management views 2026 as its first full launch year and expects a steady, 4–5-year path to peak sales.

  • More than 95% of covered lives have access; over 650 physicians had tried ZUSDURI through September, against 6,500 core targets.

  • Unique prescribers rose from just over 450 through Q2 to over 650 in Q3; repeat writers increased from 45% through Q2 to 50% in Q3.

  • Early-adopter depth has driven revenue; management aims to broaden trial and convert physicians into repeat adopters. All physicians in an ATU who tried the drug said they would use it again.

  • Management maintained a $1bn-plus peak-sales opportunity; nearly all patients in practice complete all six instillations, and anecdotal responses in heavily pretreated patients mirror clinical results.

Market and competitive landscape

  • Management sees additional therapies as expanding the bladder-cancer market rather than creating a zero-sum contest; patients may cycle through treatments, and multiple entrants can encourage practice change.

  • ZUSDURI’s differentiation is a non-surgical six-week course; cited study results include an 80% complete response rate, 80% of responders still in response at one year, and median response duration unreached at 36 months.

  • U.S. low-grade bladder cancer prevalence is 400,000, with ~15% recurring in a given year; management said first-line use would take 10–20 years to reduce the recurrent-patient pool.

Pipeline and product lifecycle

  • UGN-103 offers easier mixing, several weeks of stability after reconstitution versus seven days for the current formulation, and lyophilization in three days versus about three weeks; expected benefits include supply flexibility and modest COGS improvement.

  • UGN-103 is advancing into a high-risk papillary study later this year; management sees an opportunity among ~20,000 papillary-only patients and plans to study the product across high-grade patient types.

  • UGN-103 patents include method-of-use protection through July 2044, composition-of-matter protection to mid-2035, and RTGel protection through 2041.

  • UGN-501 dosed its first patient in a Phase I study; its dual mechanism combines direct tumor lysis with an immune response, and gel delivery is intended to extend dwell time.

  • UGN-501 may also support development beyond bladder cancer, including intratumoral treatment in other specialty cancers.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next UroGen Pharma earnings date

Logotype for UroGen Pharma Ltd
Q4 20262 Mar, 2027
UroGen Pharma
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next UroGen Pharma earnings date

Logotype for UroGen Pharma Ltd
Q4 20262 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers. The company utilizes its proprietary RTGel technology, a reverse-thermal hydrogel that enhances the therapeutic profiles of existing drugs by providing longer exposure to the urinary tract tissue, making local therapy more effective. The company is headquartered in Princeton, NJ, with operations in Israel, and its shares are listed on the Nasdaq.